Zollinger–Ellison Syndrome (Gastrinoma) – A Complete Patient Guide
Overview
Zollinger–Ellison syndrome (ZES) is a rare disorder in which one or more gastrinomas—tumors that secrete excess gastrin—lead to hyper‑acid production in the stomach. The resulting high‑acid environment can cause severe peptic ulcers, diarrhea, and malabsorption.
Most gastrinomas are malignant (cancerous) and arise in the pancreas or the duodenum (the first part of the small intestine). Approximately 0.1–0.3% of all pancreatic tumors are gastrinomas, and the overall incidence of ZES is about 0.5–2 cases per million people per year (Mayo Clinic; NIH).
While ZES can occur at any age, the average age at diagnosis is 45–55 years, and it is slightly more common in men. About 25–30% of patients have a hereditary form called multiple endocrine neoplasia type 1 (MEN‑1), which runs in families.
Symptoms
Symptoms stem from excess gastric acid and from the tumor itself. They can vary widely, making early diagnosis challenging.
- Recurrent peptic ulcers – often multiple, located in atypical sites (duodenum beyond the bulb, jejunum, or even the esophagus). Ulcers may bleed or perforate.
- Abdominal pain – burning or cramping pain that may worsen after meals.
- Diarrhea – watery, sometimes oily (steatorrhea) due to malabsorption of fats.
- Heartburn & gastro‑esophageal reflux – acid reflux is common because of the overwhelming acid load.
- Nausea & vomiting – especially after large meals.
- Weight loss – from chronic diarrhea, malabsorption, and decreased appetite.
- Fatigue & anemia – chronic blood loss from ulcers can cause iron‑deficiency anemia.
- Gastrointestinal bleeding – melena (black tarry stools) or hematemesis (vomiting blood).
- Signs of metastatic disease – if the tumor spreads to the liver or lymph nodes, patients may feel a palpable abdominal mass, have jaundice, or develop bone pain.
Causes and Risk Factors
Primary cause
Gastrinomas arise from neuroendocrine cells that normally produce gastrin, a hormone that stimulates stomach acid secretion. Genetic mutations lead to uncontrolled growth and excess gastrin release.
Key risk factors
- Multiple endocrine neoplasia type 1 (MEN‑1) – an inherited disorder caused by mutations in the MEN1 gene. Up to one‑third of ZES cases are linked to MEN‑1.
- Family history of gastrinomas or MEN‑1.
- Age – risk rises after age 40.
- Gender – slight male predominance (about 55% male).
- Smoking – may increase risk of neuroendocrine tumor development, though data are limited.
Diagnosis
Because ZES mimics common ulcer disease, a high index of suspicion is needed, especially when ulcers are refractory to standard therapy.
Laboratory tests
- Fasting serum gastrin level – > 1000 pg/mL (or > 10× upper limit) strongly suggests ZES, especially when accompanied by gastric pH < 2. A level > 150 pg/mL with low gastric pH is also diagnostic (NIH).
- Gastric pH measurement – acid output is typically high (pH < 2) even after fasting.
- Secretin stimulation test – paradoxical rise in gastrin after IV secretin distinguishes gastrinoma from other causes of hypergastrinemia.
Imaging studies
- Endoscopic ultrasound (EUS) – excellent for detecting small pancreatic or duodenal lesions.
- Multiphasic contrast‑enhanced CT or MRI – evaluates tumor size, location, and metastasis.
- Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – highly sensitive for neuroendocrine tumors, especially for occult lesions.
- Selective arterial secretin injection (SASI) test – used rarely, for precise localization when other imaging fails.
Pathology
If surgery is performed, the resected tissue is examined histologically. Gastrinomas are classified by the WHO grading system based on Ki‑67 proliferation index and mitotic rate.
Treatment Options
Management combines medical control of acid hypersecretion with definitive treatment of the tumor.
Acid‑suppression therapy (first line)
- Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are the cornerstone. Doses may be 2–4 times the usual ulcer dose and require lifelong titration.
- Histamine‑2 receptor antagonists (H2 blockers) – less effective than PPIs but can be used adjunctively.
Surgical options
- Localized tumor resection – enucleation or pancreaticoduodenectomy (Whipple) for pancreatic lesions; duodenal tumors often excised locally.
- Lymph node dissection – recommended because up to 50% of gastrinomas have nodal spread.
- Metastatic disease – hepatic metastasectomy when feasible; otherwise, ablative therapies (radiofrequency ablation, cryoablation) or embolization.
Medical therapies for unresectable or metastatic disease
- Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin secretion and may shrink tumors.
- Targeted therapy – everolimus or sunitinib for progressive neuroendocrine tumors (based on NCCN guidelines).
- Chemotherapy – limited role; streptozocin‑based regimens used in selected cases.
- Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for high‑grade somatostatin‑receptor–positive disease.
Lifestyle & supportive measures
- Small, frequent meals to reduce acid spikes.
- Avoid NSAIDs, aspirin, and alcohol—these aggravate ulcer formation.
- Supplement iron, calcium, and vitamin D if malabsorption is present.
Living with Zollinger Disease (Gastrinoma)
Daily management tips
- Medication adherence – take PPIs exactly as prescribed; never stop abruptly without a doctor’s guidance.
- Regular monitoring – check serum gastrin levels and imaging every 6‑12 months, or sooner if symptoms change.
- Nutrition – focus on low‑fat, high‑protein foods; consider a dietitian for individualized plans.
- Hydration – replace fluids lost through diarrhea; oral rehydration solutions can help maintain electrolytes.
- Vaccinations – if you receive long‑term PPIs, discuss vaccinations against Clostridioides difficile and pneumonia with your provider.
- Support networks – join patient groups (e.g., Carcinoid Cancer Foundation) for emotional support.
Follow‑up schedule
| Visit Type | Frequency | Key Assessments |
|---|---|---|
| Primary‑care/Endocrinology | Every 3–6 months | Symptoms, weight, labs (CBC, electrolytes, gastrin) |
| Gastroenterology | Every 6–12 months | Endoscopy if ulcer symptoms recur |
| Oncology/Surgeon | Every 6–12 months | Cross‑sectional imaging (CT/MRI) for tumor status |
Prevention
Because most gastrinomas arise spontaneously, primary prevention is limited. However, risk can be reduced in certain groups:
- Family screening – first‑degree relatives of MEN‑1 patients should undergo genetic counseling and annual gastrin level checks.
- Smoking cessation – lowers overall neuroendocrine tumor risk.
- Prompt treatment of chronic gastritis or H. pylori infection – does not prevent gastrinoma but reduces the background ulcer burden.
Complications
If untreated or poorly controlled, ZES can lead to serious health problems:
- Perforated ulcer – requires emergent surgery.
- Severe gastrointestinal bleeding – may need endoscopic or surgical hemostasis.
- Malabsorption & nutritional deficiencies – especially of fat‑soluble vitamins (A, D, E, K) and iron.
- Refractory peptic ulcer disease – can cause chronic pain and anemia.
- Liver metastases – most common site of spread; can cause hepatic failure.
- Bone disease – excess gastrin may affect calcium balance, leading to osteoporosis.
- Reduced quality of life – chronic pain, diarrhea, and medication side effects.
When to Seek Emergency Care
- Sudden, severe abdominal pain that does not improve.
- Vomiting blood (hematemesis) or passing black, tarry stools (melena).
- Sudden drop in blood pressure, rapid heartbeat, or fainting – possible shock from bleeding.
- High fever with worsening abdominal pain – may indicate perforation and infection.
- Profound, persistent diarrhea leading to dehydration (dry mouth, dizziness, little or no urine).
These signs can indicate a life‑threatening ulcer perforation, massive bleed, or severe infection, all of which require immediate medical attention.
References
- Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org/diseases‑conditions/zollinger‑ellison‑syndrome
- National Institutes of Health (NIH). Neuroendocrine Tumors: Diagnosis and Treatment. https://www.cancer.gov/types/neuroendocrine
- American College of Gastroenterology. Guidelines for the Management of Peptic Ulcer Disease, 2023.
- World Health Organization. Classification of Neuroendocrine Tumors, 2022.
- Cleveland Clinic. Zollinger‑Ellison Syndrome: Symptoms, Diagnosis, Treatment. https://my.clevelandclinic.org/health/diseases/
- National Comprehensive Cancer Network (NCCN). Neuroendocrine and Pancreatic Cancer Guidelines, Version 3.2024.